Last reviewed · How we verify
LY3372689
At a glance
| Generic name | LY3372689 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease (PHASE2)
- A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants (PHASE1)
- A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants (PHASE1)
- A Safety Study of LY3372689 in Healthy Participants (PHASE1)
- A Study of the Effects of LY3372689 on the Brain in Healthy Participants (PHASE1)
- A Safety Study of LY3372689 Given By Mouth to Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3372689 CI brief — competitive landscape report
- LY3372689 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI